摘要
目的:研究微生态制剂对肝硬化患者肠道菌群失调的治疗作用。方法:选择肠道菌群中具有代表性的细菌共5种进行培养和计数。选择24名正常人为对照组,计数肠道菌群中5种细菌的数量;60例肝硬化患者随机分成常规治疗组(28例)及蜡样芽孢杆菌微生态治疗组(32例),分别治疗4w,观察治疗前后肠道菌群落计数及血清脂多糖结合蛋白(LBP)的变化。结果:①肝硬化组患者存在不同程度的肠道菌群失调,主要表现为厌氧菌减少(P<0.05),而需氧菌显著增多(P<0.05);②蜡样芽孢杆菌微生态治疗组可明显提高肝硬化患者肠道厌氧菌的数量(P<0.05),降低需氧菌的数量(P<0.05),并可降低肝硬化患者血清中LBP的浓度(P<0.05)。结论:蜡样芽孢杆菌微生态制剂可有效改善肝硬化患者肠道菌群失调,并可降低血清LBP浓度,可以作为肝硬化患者的辅助治疗措施。
Objective： To investigate the effect of microecogical produces on intestinal flora in patients with liver cirrhosis. Methods： Five representative baceeriums in intestinal flora were cultivated and oounted routinely. Twenty - four healthy adults were selected as the control group. Sixty patients with liver cirrhosis were randomized into microecological produces therapeutic group and routine therapeutic group. After 4 weeks therapy, changes of the intestinal flora and lipopolysaccharide binding protein （LBP） of all subjects were detected. Results：Alteration of intestinal flora, in which anaerobic bacterium decreased and aerobic bacterium increased（P〈0. 05）, existed in patients with liver cirrhosix Bacillus cereus, one of microecological produces, could significantly increase the number of anaerobic baceerium and decrease the number of aerobic bacterium（P〈0. 05）. Further study indicated that bacillus cereus could also decrease the concentration of serum LBP in patients with liver cirrhosis（P〈0. 05）. Conclusion： Bacillus cereus can effectively improve intestinal flora and decrease the concentration of serum LBP in patients with liver cirrhosis These results suggest that bacillus cereus can serve as an adjunctive therapy for the patients with liver cirrhosis.
出处
《西南国防医药》
CAS
2008年第2期180-181,共2页
Medical Journal of National Defending Forces in Southwest China
关键词
肝硬化
肠道菌群
微生态制剂
蜡样芽孢杆菌
脂多糖结合蛋白
liver cirrhosis
intstinal flora
microecological products
bacillus cereus lipopolysaccharide binding protein
